During perimenopause, women with catamenial epilepsy generally experience an increase in seizure frequency, and HRT use does not change this likelihood.
Women progressing through peri- and post-menopause using HRT may be in greater need of anticonvulsant medication monitoring to maintain or reduce seizure occurrence.
Upon completion of the certification exercise, the HRT began to expand its capabilities by sending small teams of operators out for more specialized training courses.
Current users of estrogen-progestogen HRT were at 2 fold increased risk of developing breast cancer, and current users of estrogen-only HRT at 1.3 fold risk.